Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 6/20 | 0.40 |
| ▸ | MMP1 | P03956 | 4/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 3/20 | 0.39 |
| ▸ | MMP3 | P08254 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6757111 | 0.91 | KDM4E (0.47) | ADAM17KDM4EALDH1A1TDP1MMP13 | |
| SCHEMBL6865929 | 0.86 | ADAM17 (0.53) | ADAM17ALDH1A1MMP13MMP1MMP9 | |
| Hydroxyamine SCHEMBL6865560 | 0.83 | ADAM17 (0.39) | ADAM17MMP13MMP1MMP9MMP2 | |
| SCHEMBL6863576 | 0.82 | ADAM17 (0.56) | ADAM17MMP13MMP1MMP9 | |
| Hydroxyamine SCHEMBL6865557 | 0.79 | ADAM17 (0.35) | ADAM17ALDH1A1MMP13MMP1MMP9 | |
| SCHEMBL6864517 | 0.78 | KDM4E (0.47) | ADAM17KDM4EALDH1A1MMP13MMP1 | |
| Hydroxyamine SCHEMBL4033564 | 0.76 | ADAM17 (0.83) | ADAM17KDM4EALDH1A1TDP1MMP13 | |
| SCHEMBL6261871 | 0.74 | ADAM17 (0.86) | ADAM17KDM4EALDH1A1TDP1MMP13 | |
| Hydroxyamine SCHEMBL7463488 | 0.73 | S1PR5 (0.52) | ADAM17ALDH1A1MMP13MMP1MMP9 | |
| SCHEMBL7506020 | 0.73 | S1PR5 (0.53) | ADAM17MMP13MMP1MMP9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | WYETH | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229924-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors | MMP17, MMP1, MMP9 | ADAM17 12/4885KDM4E 2567/4885ALDH1A1 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.